Prediction of Response to Preoperative Chemoradiotherapy in Rectal Cancer by Using Reverse Transcriptase Polymerase Chain Reaction Analysis of Four Genes
Authors:
- 1 January 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 57 (1) , 23-31
Abstract
Patients with rectal cancer exhibit a wide spectrum of responses to chemoradiotherapy. Several gene expression signatures have been reported to predict the response to chemoradiotherapy in rectal cancer, but the lack of practical assays has restricted the clinical use of this technique. We aimed to identify a set of discriminating genes that can be used for the clinical prediction of response to chemoradiotherapy in rectal cancer. This study is a retrospective analysis of tumor samples in a single institute. Sixty-two patients who underwent preoperative chemoradiotherapy were studied. Gene expression was initially studied in 46 training samples by microarray analysis, and the association between gene expression and response to chemoradiotherapy was evaluated. Quantitative reverse transcriptase polymerase chain reaction was performed to validate the microarray expression levels of the discriminating genes. We developed a gene expression model for the prediction of response to chemoradiotherapy based on the reverse transcriptase polymerase chain reaction findings and validated it by using 16 independent test samples. We identified 24 discriminating probes with expression levels that differed significantly between responders and nonresponders. Among 18 genes identified by Gene Symbol, real-time reverse transcriptase polymerase chain reaction showed significant differences in the expression of 16 genes between responders and nonresponders. We constructed a predictive model by using different sets of these 16 genes, and the highest accuracy rate (89.1%) was obtained by using LRRIQ3, FRMD3, SAMD5, and TMC7. The predictive accuracy rate of this 4-gene signature in the independent set of 16 patients was 81.3%. Validation in a different and large cohort of patients is necessary. The 4-gene signature identified in this study is closely associated with response to chemoradiotherapy in rectal cancer.Keywords
This publication has 28 references indexed in Scilit:
- Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal CancerJournal of Clinical Oncology, 2009
- Microarray-Based Prediction of Tumor Response to Neoadjuvant Radiochemotherapy of Patients With Locally Advanced Rectal CancerClinical Gastroenterology and Hepatology, 2008
- Microarray Gene Expression Profiling for Predicting Complete Response to Preoperative Chemoradiotherapy in Patients with Advanced Rectal CancerDiseases of the Colon & Rectum, 2007
- A Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2007
- Chemotherapy with Preoperative Radiotherapy in Rectal CancerNew England Journal of Medicine, 2006
- Prediction of Sensitivity of Rectal Cancer Cells in Response to Preoperative Radiotherapy by DNA Microarray Analysis of Gene Expression ProfilesCancer Research, 2006
- Effectiveness of Gene Expression Profiling for Response Prediction of Rectal Adenocarcinomas to Preoperative ChemoradiotherapyJournal of Clinical Oncology, 2005
- Preoperative versus Postoperative Chemoradiotherapy for Rectal CancerNew England Journal of Medicine, 2004
- Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six GenesNew England Journal of Medicine, 2004
- Prognostic Model of Pulmonary Adenocarcinoma by Expression Profiling of Eight Genes As Determined by Quantitative Real-Time Reverse Transcriptase Polymerase Chain ReactionJournal of Clinical Oncology, 2004